Tetanus in ethiopia: Unveiling the blight of an entirely vaccine-preventable disease

Current Neurology and Neuroscience Reports

Volumn 12, Issue 6, 2012, Pages 655-665

  Woldeamanuel, Yohannes Woubishet ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

Ethiopia; Maternal and neonatal tetanus; Tetanus; Tetanus vaccination

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHLORPROMAZINE; CLINDAMYCIN; DIAZEPAM; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPARIN; MACROLIDE; MAGNESIUM SULFATE; METRONIDAZOLE; PENICILLIN G; TETANUS TOXOID; VERAPAMIL;

ABORTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD HEALTH CARE; DEEP VEIN THROMBOSIS; DEVELOPED COUNTRY; DRUG STORAGE; ETHIOPIA; FAMILY PLANNING; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; INTENSIVE CARE; INTENSIVE CARE UNIT; LEPROSY; MALARIA; MORTALITY; MUSCLE SPASM; PATIENT COMPLIANCE; PATIENT MONITORING; PLACENTAL TRANSFER; POST EXPOSURE PROPHYLAXIS; PRENATAL CARE; PREVALENCE; RURAL POPULATION; SHOE; TERTIARY HEALTH CARE; TETANUS; TETANUS PROPHYLAXIS; TREND STUDY; WOUND CARE;

DELIVERY OF HEALTH CARE; DISEASE MANAGEMENT; ETHIOPIA; HUMANS; RURAL POPULATION; TETANUS; TETANUS TOXOID; VACCINATION;

EID: 84870481418     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0314-3     Document Type: Article

References (120)

1. GNI per capita, PPP (current international $). Available at: data.worldbank.org/indicator/NY.GNP.PCAP.PP.CD/countries. Accessed June 16, 2012.
2. Central Statisitcal Agency, A.A., Ethiopia, Ethiopia Demographic and Health Survey, 2012.
3. WHO, The global burden of disease. 2004; update, 2008.
4. Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. J Neurol Sci. 2012;317:62-5.
5. Tadesse H, Deribew A, Woldie M. Predictors of defaulting from completion of child immunization in south Ethiopia, May 2008-a case control study. BMC Publ Health. 2009;9:150.
6. Woldeamanuel YW, Hassan A. Tetanus weighs on neurological burden in Ethiopia. World Neurol. 2010;25:14.
7. Amare A, Yami A. Case-fatality of adult Tetanus at Jimma University Teaching Hospital, Southwest Ethiopia. Afr Health Sci. 2011;11:36-40.
8. Worku T, Bayou A, Aseffa A. Tetanus in a rural hospital in Northeast Ethiopia. Ethiopian J Health Dev. 2004;18:55-6.
9. Amsalu S, Lulseged S. Tetanus in a children's hospital in Addis Ababa: review of 113 cases. Ethiopia Med J. 2005;43:233-40.
10. Hodes RM, Teferedegne B. Tetanus in Ethiopia: analysis of 55 cases from Addis Ababa. East Afr Med J. 1990;67:887-93.
11. Nida H. Neonatal tetanus in Awassa: retrospective analysis of patients admitted over 5 years. Ethiopia Med J. 2001;39:241-6.
12. Ogunrin O. Tetanus-a review of current concepts in management. J Postgrad Med. 2009;11:46-61.
13. Atkinson W, Wolfe C, Hamborsk J, editors. Tetanus, in epidemiology and prevention of vaccine-preventable diseases. Washington: Public Health Foundation; 2011. p. 291-300.
14. Cherry J, Harrison R. Tetanus. In: Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases. Philadelphia: Elsevier; 2004. p. 1766-76.
15. Bleck T. Clostridium tetani. In: Mandell GL, Bennett JE, Dolin R, editors. Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 1995. 9-p. 2373-8.
16. Alene G. Harmful traditional health practices: a cross-sectional survey among under-five children in Dembia district, northwest Ethiopia. Ethiopia J Health Biomed Sci. 2010;2:83-93.
17. WHO. Podoconiosis: endemic non-filarial elephantiasis. 2012 (cited 2012 29/05/12).
18. Simmonsen O, Block A, Heron I. Epidemiology of tetanus in Denmark 1920-1982. Scand J Infect Dis. 1987;19:437-44.
19. Roper M, Vandelaer J, Gasse F. Maternal and neonatal tetanus. Lancet. 2007;370:1947-59.
20. WHO. Immunization profile - Ethiopia 2012. Available at: apps.who.int/immunization-monitoring/en/globalsummary/countryprofileresult.cfm? C0eth. Accessed June 16, 2012.
21. Poverty Reduction and Immunizations. Considering immunizations in the context of debt relief for poor countries. Prepared for: the Bill & Melinda Gates Children's Vaccine Program at PATH, 2000: Bethesda, Maryland. Available at: www.path.org/files/PovertyReductionImmunizations-Abt.pdf. Accessed June 16, 2012.
22. Outsourcing the vaccine supply chain and logistics system to the private sector: the Western Cape Experience in South Africa. PATH, World Health Organization. 2011;Seattle:PATH. 2011. Available at: www.path.org/publications/ files/TS-opt-outsourcing-sa.pdf. Accessed June 16, 2012.
23. Temperature sensitivity of vaccines. Immunization, vaccines and biologicals. World Health Organization. 2006: Geneva, Switzerland. Available at: www.who.int/vaccines-documents/DocsPDF06/847.pdf. Accessed June 16, 2012.
24. Health and Health Related Indicators, 2009/10. Federal Ministry of Health - Ethiopia, Ethiopian Calendar 2002. Available at: www.moh.gov.et/English/ Resources/Documents/HealthandHealthRelatedIndicator2002.pdf. Accessed June 16, 2012.
25. Kidane T, Yigzaw A, Sahilemariam Y, Bulto T, Mengistu H, Belay T, et al. National EPI coverage survey report in Ethiopia, 2006. Ethiopia J Health Dev. 2008;22:148-57.
26. Using immunization coverage rates for monitoring health sector performance: measurement and interpretation issues. HNP Discussion Series. Bose and Batson A. Health, nutrition, population discussion paper, August 2000: Washington, DC. Available at: siteresources.worldbank.org/ HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/Bos- UsingImmunization-whole.pdf. Accessed June 16, 2012.
27. Immunization surveillance, assessment and monitoring. Maternal and Neonatal Tetanus (MNT) elimination. Progress towards global MNT elimination. World Health Organization. January 2012. Available at: www.who.int/immunization- monitoring/diseases/MNTE-initiative/en/index4.html. Accessed June 16, 2012.
28. UNICEF-Ethiopia. Immunization plus. Polio, measles and MNTE activities. Avaliable at: www.unicef.org/ethiopia/immunization.html. Accessed June 16, 2012.
29. Investing in boys and girls in Ethiopia. Past, present and future, UNICEF-Ethiopia and Ministry of Finance and Economic Development, 2012. Available at: www.unicef.org/ethiopia/ET-SITAN-boys-girls.pdf. Accessed June 16, 2012.
30. Using early childhood booster doses to maintain the elimination of Neonatal Tetanus. Steinglass R. Based on a paper delivered at the World Health Organization (WHO) Neonatal Tetanus Elimination Technical Consultation, Geneva, 1997. Available at: pdf.usaid.gov/pdf-docs/PNACN105.pdf. Accessed June 16, 2012.
31. Galazka A. The immunological basis for immunization. Module 3: tetanus. Global programme for vaccines and immunization. Geneva: Expanded Programme on Immunization; 1996.
32. Naimoli JF, Challa S, Schneidman M, Kostermans K. Toward a grounded theory of why some immunization programs in sub-Saharan Africa are more successful than others: a descriptive and exploratory assessment in 6 countries. Health Policy Plann. 2008:23:379-89.
33. England S. "The evidence base for interventions to reduce mortality from vaccine-preventable diseases in low and middleincome Countries" (Geneva: Commission on Macroeconomics and Health, Working Paper Series, June 5, 2001) 2001.
34. Bloom D, Canning D, Weston M. The value of vaccination. World Econ. 2004;6:15-39.
35. Miguel E, Kremer M. Worms: identifying impacts on education and health the presence of treatment externalities. Econometrica. 2004;72:159-217.
36. Bawah AA, Phillips JF, Adjuik M, Vaughan-Smith M, Macleod B, Binka FN. The impact of immunization on the association between poverty and child survival: evidence from Kassena-Nankana District of northern Ghana. Scand J Publ Health. 2010;38:95-103.
37. Mekonen Y. Missed opportunity of tetanus toxoid immunization among pregnant women in Southern Ethiopia. Ethiopian J Health Dev. 2000;14:143-8.
38. WHO. Tetanus vaccine: WHO position paper. Wkly Epidemiol Rec. 2006;81:198-208.
39. CDC, Recommended immunization schedules for persons aged 0 through 18 years, United States 2012. Available at: www.cdc.gov/vaccines/schedules/ downloads/child/0-18yrs-11x17-fold-pr.pdf. Accessed June 16, 2012.
40. Maru M, Getahun A, Hosana S. A house-to-house survey of neonatal tetanus in urban and rural areas in the Gondar region, Ethiopia. Trop Geogr Med. 1988;40:233-6.
41. UNICEF-Ethiopia. Maternal and neonatal tetanus. 2004. Available at: www.unicef.org/ethiopia/ET-media-MNTE.pdf. Accessed June 16, 2012.
42. Kidane T. Factors influencing TT immunization coverage and protection at birth coverage in Tselemi District, Ethiopia. Ethiopia J Health Dev. 2004;18:153-8.
43. Steinglass R. Eliminating neonatal tetanus, excerpted from basic support for institutionalizing child survival project (BASICS II) for the United States Agency for International Development. Arlington, Virginia, June 2001.
44. Ramos JM, Reyes F, Tesfamariam A. Tetanus in a rural Ethiopian hospital. Trop Doct. 2008;38:104-5.
45. Habte-Gabr E, Mengistu M. Tetanus in Gondar Public Health College Hospital, Ethiopia: a review of 72 cases. Ethiopia Med J. 1978;16:53-61.
46. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (online). 2010;375:1969-87.
47. UNICEF, Maternal and neonatal tetanus elimination initiative. Pampers UNICEF 2010 campaign launch. Available at: http://www.unicef.org/corporate- partners/files/APPROVED-MNT-Report-05.06.10.pdf. Accessed June 16, 2012.
48. Stanfield J, Galazka A. Neonatal tetanus in the world today. Bull World Health Organ. 1984;62:647-69.
49. Meegan ME, Conroy RM, Lengeny SO, Renhault K, Nyangole J. Effect on neonatal tetanus mortality after a culturally-based health promotion programme. Lancet. 2001;358:640-1.
50. Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. Tetanus in developing countries: an update on the maternal and neonatal tetanus elimination initiative. Vaccine. 2003;21:3442-5.
51. Brenzel L, Wolfson LJ, Fox-Rushby J, Miller M, Halsey NA. Vaccine-preventable disease. In: Jamison D, Breman J, Measham J, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. p. 389-411.
52. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367:1193-208.
53. Ehreth J. The global value of vaccination. Vaccine. 2003;21:596-600.
54. UNICEF. Maternal and neonatal elimination by 2005. Strategies for achieving and maintaining elimination. 2000. Available at: www.unicef.org/ health/files/MNTE-strategy-paper.pdf. Accessed June 16, 2012.
55. United Nations Millenium Development Goals. A gateway to the UN system's work on the MDGs. Available at: www.un.org/milleniumgoals. Accessed June 16, 2012.
56. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance - United States. MMWR Surveill Summ. 2003;52:1-8.
57. Wassila S, et al. Tetanus toxoid. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. Philadelphia: Saunders; 2008. p. 805-39.
58. Deressa W, Ali A. Malaria-related perceptions and practices of women with children under the age of five years in rural Ethiopia. BMC Publ Health. 2009;9:259.
59. Hadgu P, Tsega E, Geremew S. Tetanus: review of the literature and outline of prophylaxis and management. Ethiopia Med J. 1975;1:161-70.
60. Brabin BJ, Nagel J, Hagenaars AM, Ruitenberg E, van Tilborgh AM. The influence of malaria and gestation on the immune response to one and two doses of adsorbed tetanus toxoid in pregnancy. Bull, Geneva, World Health Organ. 1984;62:919-30.
61. Ethiopian Aids Resource Center. National factsheet 2010. AIDS in Ethiopia main indicators 2010. Available at: http://www.etharc.org/resources/healthstat/ nationalfactsheet/13-nationalfactsheet2010. Accessed June 16, 2012.
62. WHO, Immunization policy, global programme for vaccines and immunization 1996: Geneva, Switzerland. Available at: http://whqlibdoc.who.int/hq/1995/WHO- EPI-GEN-95.03-Rev.1.pdf. Accessed June 16, 2012.
63. Blanche S, Le Deist F, Fischer A, Veber F, Debre M, Chamaret S, et al. Longitudinal study of 18 children with perinatal LAV/HTLV infection: attempt at prognostic evaluation. J Pediatr. 1986;109:965-70.
64. Kurtzhals JA, Kjeldsen K, Heron I, Skinhøj P. Immunity against diphtheria and tetanus in human immunodeficiency virus -infected Danish men born 1950-1959. APMIS. 1992;100:803-8.
65. Kroon F. Immunoglobulin (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol. 1999;6:352-5.
66. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bulletin, Geneva, World Health. Organization. 2003;81:6170.
67. de Moraes-Pinto MI, Almeida AC, Kenj G, Filgueiras TE, Tobias W, Santos AM, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. 1996;173:1077-84.
68. Okoko J, Wesumperuma H, Hart C. The influence of prematurity and low birthweight on transplacental antibody transfer in a rural west African population. Trop Med Int Health. 2001;6:529-34.
69. de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, et al. Placental antibody transfer: influence ofmaternal HIVinfection and placentalmalaria. Arch Dis Child Fetal Neonatal Ed. 1998;79:202-5.
70. Okoko BJ, Wesuperuma LH, Ota MO, Banya WA, Pinder M, Gomez FS, et al. Influence of palcental malaria infection and maternal hypergammaglobulinema on materno-foetal transfer of measles and tetanus antibodies in a rural west African population. J Health Popul Nutr. 2001;19:59-65.
71. FMOH-Ethiopia, Tuberculosis, Leprosy and TB/HIV prevention and control programme, 2008. Addis Ababa.Available at: http://www.who.int/hiv/pub/ guidelines/ethiopia-tb.pdf. Accessed June 16, 2012.
72. Hodes R, Teferedegne B. Tetanus in leprosy patients: report of five cases. Int J Lepr Other Mycobact Dis. 1988;56:228-30.
73. Singh M, Kumar B, Ayagiri A, Kaur S. Natural tetanus immunity in lepromatous leprosy patients. Indian J Lepr. 1986;58:91-5.
74. Dharmendra SH. Leprosy. Bombay: Kothari Publishing House; 1978. p. I.
75. Goodwin D, Wood M. Bacteria isolated from plantar ulcers of Ethiopian leprosy patients with antibacterial drug sensitivities of the isolates. Trans R Soc Trop Med Hyg. 1970;64:421-6.
76. Guilfoile P. Deadly diseases and epidemics: tetanus. In: Babock H, editor. Deadly diseases and epidemics. New York: Infobase Publishing; 2008. p. 100.
77. Berger SA, Cherubin CE, Nelson S, Levine L. Tetanus despite preexisting antitetanus antibody. JAMA. 1978;240:769-70.
78. Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF. [Les anticorps antitetaniques. Titrage avant seroanatoxionotherapie chez 64 tetaniques]. Nouv Presse Med. 1972;1:3049-50.
79. Passen E, Andersen B. Clinical tetanus despite a "protective" level of toxin-neutralizing antibody. JAMA. 1986;255:1171-3.
80. Matzkin H, Regev S. Naturally acquired immunity to tetanus in an isolated community. Infect Immun. 1985;48:267-8.
81. Ray SN, Ray K, Grover SS, Sharma RS, Sharma SP. Sero-survey of diphtheria and tetanus antitoxin. Indian J Med Res. 1978;68:901-4.
82. Veronesi R, Cecin H, Corrêa A, Tavares J, Moraes C, Bertoldo OJ. New concepts in tetanus immunization: naturally acquired immunity. J Hyg Epidemiol Microbiol Immunol. 1975;19:126-34.
83. Veronesi R, Bizzini B, Focaccia R, Coscina AL, Mazza CC, Focaccia MT, et al. Naturally acquired antibodies to tetanus toxin in humans and animals from Galapagos Islands. J Infect Dis. 1983;147:308-11.
84. Dastur FD, Awatramani VP, Dixit SK, D'Sa JA, Cooverji ND, Anand MP. Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin. Lancet. 1981;2:219-22.
85. MacLennan R, Schofield FD, Pittman M, Hardegree MC, Barile MF. Immunization against neonatal tetanus in New Guinea: antitoxin response of pregnant women to adjuvant and plain toxoids. Bull, Geneva, World Health Organ. 1965;32:683-97.
86. Breman JG, Wright GG, Levine L, Latham WC, Compaoré KP. The primary serological response to a single dose of adsorbed tetanus toxoid, high concentration type. Bull, Geneva, World Health Organ. 1981;59:745-52.
87. Menon PS, Sahai G, Joshi VB, Murthy RG, Boparai MS, Thomas AK. Field trial on frozen and thawed tetanus toxoid. Indian J Med Res. 1976;64:25-32.
88. Borrow R, Balmer P, Roper M. The immunological basis for immunization series. Module 3: tetanus. Geneva, Switzerland: WHO Document Production Services. 2006.
89. Trujillo MH, Castillo A, España J, Manzo A, Zerpa R. Impact of intensive care management on prognosis of tetanus: analysis of 641 cases. Chest. 1987;92:63-5.
90. Melaku Z, Alemayehu M, Oli K, Tizazu G. Pattern of admissions to the medical intensive care unit of Addis Ababa University Teaching Hospital. Ethiopia Med J. 2006;44:33-42.
91. Afshar M, Raju M, Ansell D, Bleck TP. Narrative review: tetanus-a health threat after natural disasters in developing countries. Ann Intern Med. 2011;154:329-35.
92. Shibuya M, Sugimoto H, Sugimoto T, Shimazu T, Uenishi M, Yoshioka T. The use of continuous spinal anesthesia in severe tetanus with autonomic disturbance. J Trauma. 1989;29:1423-9.
93. Vassa NT, Doshi HV, Yajnik VH, Shah SS, Joshi KR, Patel SH. Comparative clinical trial of diazepam with other conventional drugs in tetanus. Postgrad Med J. 1974;50:755-8.
94. Saissy JM, Demazière J, Vitris M, Seck M, Marcoux L, Gaye M, et al. Treatment of severe tetanus by intrathecal injections of baclofen without artificial ventilation. Intensive Care Med. 1992;18:241-4.
95. Engrand N, Guerot E, Rouamba A, Vilain G. The efficacy of intrathecal baclofen in severe tetanus. Anesthesiology. 1999;90:1773-6.
96. Salimpour R. Tetanus of the newborn in Tehran. A ten year study of 880 cases. J Trop Pediatr Environ Child Health. 1978;24:140-2.
97. Ertem M, Cakmak A, Saka G, Ceylan A. Neonatal tetanus in the South-Eastern region of Turkey: changes in prognostic aspects by better health care. J Trop Pediatr Environ Child Health. 2004;50:297-300.
98. Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368:1436-43.
99. King W, Cave D. Use of esmolol to control autonomic instability of tetanus. Am J Med. 1991;91:425-8.
100. Sutton DN, Tremlett MR, Woodcock TE, Nielsen MS. Management of autonomic dysfunction in severe tetanus: the use of magnesium sulphate and clonidine. Intensive Care Med. 1990;16:75-80.
101. Buchanan N, Cane RD, Wolfson G, De Andrade M. Autonomic dysfunction in tetanus: the effects of a variety of therapeutic agents, with special reference to morphine. Intensive Care Med. 1979;5:65-8.
102. Kerr JH. Insensible fluid losses in severe tetanus. Intensive Care Med. 1981;7:209-12.
103. Wright DK, Lalloo UG, Nayiager S, Govender P. Autonomic nervous system dysfunction in severe tetanus: current perspectives. Crit Care Med. 1989;17:371-5.
104. Buchanan N, Smit L, Cane RD, De Andrade M. Sympathetic overactivity in tetanus: fatality associated with propanolol. BMJ. 1978;2:254-5.
105. Joshi S, Agrawal B, Malla G, Karmacharya B. Complete elimination of tetanus is still elusive in developing countries: a review of adult tetanus cases from referral hospital in Eastern Nepal. Kathmandu Univ Med J (KUMJ). 2007;5:378-81.
106. Gibson K, Bonaventure Uwineza J, Kiviri W, Parlow J. Tetanus in developing countries: a case series and review. Can J Anaesth. 2009;56:307-15.
107. Handel J, McCallum D. A different form of nutrition delivery. Hosp Update. 1995;21:270-7.
108. Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth. 2001;87:477-87.
109. Griggs WM, Worthley LI, Gilligan JE, Thomas PD, Myburg JA. A simple percutaneous tracheostomy technique. Surg Gynae Obs. 1990;170:543-5.
110. Singh S, Fetters T, Gebreselassie H, Abdella A, Gebrehiwot Y, Kumbi S, et al. The estimated incidence of induced abortion in Ethiopia. Int Perspect Sex Reproduct Health. 2010;36:16-25.
111. Gebreselassie H, Fetters T, Singh S, Abdella A, Gebrehiwot Y, Tesfaye S, et al. Caring for women with abortion complications in Ethiopia: national estimates and future implications. Int Perspect Sex Reproduct Health. 2010;36:6-15.
112. Brabin L, Kemp J, Maxwell SM, Ikimalo J, Obunge OK, Briggs ND. Protecting adolescent girls against tetanus. BMJ. 1995;311:73-4.
113. Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol. 2001;75:11474-82.
114. Elkharrat D, Espinoza P, De la Coussaye J, Potel G, Pourriat JL, Sanson-Le Pors MJ. [Inclusion of a rapid test in the current Health Ministry Guidelines with the purpose of improving anti-tetanus prophylaxis prescribed to wounded patients presenting at French Emergency Departments]. (Article in French). Med Mal Infect. 2005;35:323-8.
115. Hashem FM, Fahmy SA, El-Sayed AM, Al-Sawahli MM. Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice. Pharm Dev Technol. 2011. doi:10.3109/10837450.2011.618949
116. Baxendale A, van Hooff P, Durrant LG, Spendlove I, Howdle SM, Woods HM, et al. Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology. Int J Pharm. 2011;413:147-54.
117. Merhai Z, Kumar A. Tetanus in infancy and childhood (a review of 110 cases from Addis Ababa, Ethiopia). East Afr Med J. 1986;63:736-41.
118. George AO, Ogunbiyi AO, Amanor-Boadu S, Oluwole OA, Kumuyi O. Tetanus in Nigeria: the economic burden. Trop Doct. 2005;35:126-7.
119. Health statistics and health information systems. Metrics: Disability-Adjusted Life Year (DALY) Quantifying the burden of disease from mortality and morbidity. Available at: http://www.who.int/healthinfo/global- burden-disease/metrics-daly/en/. Accessed August 29, 2012.
120. GNI, PPP (current international $) Available at: http://data.worldbank.org/indicator/NY.GNP.MKTP.PP.CD. Accessed August 29, 2012.